Nusano

Executive Summary

Nusano is a privately held physics company pioneering a novel particle acceleration platform to transform the production of medical radioisotopes. By addressing critical supply chain vulnerabilities, the company aims to ensure a reliable, high-volume supply of isotopes essential for next-generation cancer diagnostics and radiotherapeutics. Additionally, Nusano's technology holds potential for applications in energy and critical minerals recovery, broadening its addressable market. Founded in 2021 and headquartered in Salt Lake City, Utah, the company operates at the intersection of physics and radiopharmaceuticals, targeting an industry where isotope shortages have hindered treatment adoption. As a preclinical-stage venture, Nusano's near-term focus is on demonstrating its technology at scale, securing strategic partnerships with radiopharmaceutical developers, and raising growth capital. The growing global demand for targeted radionuclide therapies, coupled with the need for diversified isotope supply sources, positions Nusano as a compelling player in the radiopharmaceutical ecosystem. Key upcoming catalysts include progress toward commercial production, potential pharma collaborations, and follow-on financing events that could validate its platform and accelerate commercialization.

Upcoming Catalysts (preview)

• Q4 2026Initial commercial radioisotope production run65% success
• 2027Strategic partnership with a radiopharmaceutical company50% success
• Q3 2026Completion of Series B financing round75% success